• ACU301 and ACU401 were nominated in the EBD program as part of the exercise of Acumen's option under its license agreement with JCR Pharmaceuticals
  • EBD technology represents the only anti-amyloid oligomer program combining a validated blood-brain barrier-penetrating technology with a therapeutic antibody tested in the clinic
  • Acumen's EBD candidates are designed to achieve higher brain penetration with potential for improved safety compared to native antibodies and delivered in a stable, low volume subcutaneous administration format
  • Investigational New Drug (IND)-enabling activities are ongoing to support IND submission in mid-2027